SAO PAULO (Reuters) – Sinovac Biotech’s vaccine versus COVID-19 is over 50?ficient in late-stage trials, paper Folha de S. Paulo reported on Wednesday, including that the Chinese business had actually asked the Brazilian institute running tests to wait approximately 15 days prior to releasing their full results.
The Butantan Institute, which is running the trial in Brazil, and the government of Sao Paulo, which manages the institute, decreased to comment, saying there would be more information in a news conference at 4 p.m. regional time.
If researchers keep back the complete outcomes, it would be the third time the institute has actually done so, after originally assuring to offer effectiveness information in early December. Any delay would represent an obstacle in Beijing’s efforts to overtake Western drugmakers in the fight to check the pandemic.
Sinovac would be the 2nd Chinese vaccine maker to produce results from late-stage medical trials, after United Arab Emirates said this month that a vaccine from a Beijing-based unit of China National Pharmaceutical Group (Sinopharm) has 86?fectiveness.
Competing products established by AstraZeneca Plc, Pfizer and Moderna produced favorable results with more details in November.
Reuters Health Info ©2020
Cite this: Sinovac’s COVID-19 Vaccine Over 50?fective in Brazil Tests, Reports Newspaper Folha – Medscape – Dec 23, 2020
No comments:
Post a Comment